Zacks Research Issues Positive Outlook for Glaukos Earnings

Glaukos Co. (NYSE:GKOS) – Analysts at Zacks Research lifted their FY2024 earnings estimates for shares of Glaukos in a report released on Monday, November 25th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will post earnings per share of ($1.98) for the year, up from their prior forecast of ($2.32). The consensus estimate for Glaukos’ current full-year earnings is ($1.96) per share. Zacks Research also issued estimates for Glaukos’ Q4 2024 earnings at ($0.48) EPS, Q1 2025 earnings at ($0.36) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.22) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.23) EPS.

Glaukos (NYSE:GKOS) last issued its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. The firm had revenue of $96.70 million for the quarter, compared to analysts’ expectations of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm’s revenue for the quarter was up 23.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.50) earnings per share.

Several other equities research analysts also recently issued reports on GKOS. JPMorgan Chase & Co. boosted their price objective on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. StockNews.com upgraded Glaukos from a “sell” rating to a “hold” rating in a report on Monday, October 21st. Wells Fargo & Company boosted their price objective on Glaukos from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Piper Sandler set a $140.00 target price on Glaukos in a research note on Thursday, October 17th. Finally, BTIG Research boosted their price target on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Tuesday. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Glaukos has an average rating of “Moderate Buy” and an average target price of $135.45.

Glaukos Stock Up 1.4 %

Shares of NYSE:GKOS opened at $142.68 on Thursday. Glaukos has a 1 year low of $59.58 and a 1 year high of $146.86. The stock has a 50-day simple moving average of $133.15 and a 200-day simple moving average of $124.27. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The stock has a market capitalization of $7.87 billion, a P/E ratio of -47.25 and a beta of 1.02.

Hedge Funds Weigh In On Glaukos

Hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP raised its holdings in shares of Glaukos by 294.5% during the third quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock worth $284,501,000 after purchasing an additional 1,630,270 shares during the period. Point72 Asset Management L.P. acquired a new stake in Glaukos during the second quarter worth about $67,460,000. Primecap Management Co. CA lifted its holdings in Glaukos by 43.9% in the second quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier’s stock worth $144,483,000 after acquiring an additional 372,180 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Glaukos by 148.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier’s stock valued at $48,805,000 after acquiring an additional 246,322 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Glaukos by 47.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier’s stock valued at $83,609,000 after purchasing an additional 207,338 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Transactions at Glaukos

In related news, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the sale, the director now owns 32,336 shares in the company, valued at $4,225,345.12. The trade was a 8.49 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.